Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A M StoppaD Maraninchi

Abstract

To demonstrate the feasibility and efficacy of six ambulatory high-dose sequential chemotherapy courses that include three intensified cycles supported by stem-cell infusion in high-risk and high-intermediate-risk untreated non-Hodgkin's lymphoma (NHL) patients. A pilot nonrandomized study included 20 untreated patients aged less than 60 years with aggressive histologically identified NHL and two or three adverse-prognosis criteria (International Index). Patients received an ambulatory regimen with high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF) and repeated peripheral-blood stem-cell (PBSC) infusion. The median age was 39 years (range, 20 to 59), with 13 men and seven women. Chemotherapy consisted of one cycle every 21 days for a total of six cycles. The first three cycles (A1, A2, and A3) consisted of cyclophosphamide (Cy) 3,000 mg/m2, doxorubicin (Doxo) 75 mg/m2, and vincristine 2 mg (plus corticosteroids). The last three cycles (B4, B5, and B6) consisted of the same drug combination plus etoposide 300 mg/m2 and cisplatin 100 mg/m2. For an expected duration of 18 weeks, the projected dose-intensity was 25 mg/m2/wk for Doxo and 1,000 mg/m2/wk for Cy. G-CSF 300 micrograms was administered from...Continue Reading

Citations

Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H TillyB Coiffier
Jun 25, 2003·Expert Review of Anticancer Therapy·Marcie Tomblyn, Jane N Winter
May 25, 2004·Leukemia & Lymphoma·Robert Marcus
Apr 21, 2001·Bone Marrow Transplantation·A SalarUNKNOWN GEL/TAMO Spanish Cooperative Group
Oct 19, 2001·Bone Marrow Transplantation·K P PapadopoulosC S Hesdorffer
Apr 21, 2001·Bone Marrow Transplantation·J M VantelonV Ribrag

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Julie M VoseJames O Armitage
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J E HardinghamB M Dale
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Julie M VoseAutologous Blood and Marrow Transplant Registry Lymphoma Working Committee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Julie M VoseJ O Armitage
© 2021 Meta ULC. All rights reserved